Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lindane is an organochlorine insecticide and ectoparasiticide used as a second-line topical treatment for scabies and lice infestations in humans. It is available as a cream or lotion for scabies and as a shampoo for lice. Lindane acts by blocking the Gamma-aminobutyric acid type A receptor (GABA_A receptor)-chloride channel complex in parasites (and humans), leading to neuronal hyperexcitation and death of the parasite. Due to its neurotoxicity risk—including seizures and rare fatalities—lindane is reserved for patients who cannot tolerate or have failed safer first-line therapies such as permethrin. Lindane has been banned or restricted in many countries due to environmental concerns and toxicity but remains FDA-approved in the United States for limited use[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lindane.